酒石酸卡巴拉汀 T1628

Product Introduction
Bioactivity


英文名: Rivastigmine tartrate

描述: Rivastigmine tartrate (SDZ-ENA 713) 是一种具有口服活性的、可透过血脑屏障的胆碱酯酶抑制剂，能够抑制丁酰胆碱酯酶和乙酰胆碱酯酶。它是一种拟副交感神经剂或胆碱能剂，用于研究轻度至中度阿尔茨海默氏型痴呆和帕金森氏病引起的痴呆。

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: Ethanol : 74 mg/mL (184.8 mM)
DMSO : 39 mg/mL (97.4 mM)
H2O : 73 mg/mL (182.3 mM)


关键字: ENA-713 | BBB | cholinesterase | acetylcholinesteras | BChE | disease | orally | butyrylcholinesterase | Inhibitor | Alzheimer's | Rivastigmine tartrate | Parkinson's | SDZ-ENA-713 | Cholinesterase (ChE) | ENA713 | ChE | Rivastigmine Tartrate | SDZ-ENA713 | Rivastigmine | cholinergic | inhibit | parasympathomimetic

相关产品: Pempidine | Nitrocaramiphen hydrochloride | Dibucaine hydrochloride | Ipratropium Bromide | SKF-83566 | VU0453595 | Orphenadrine | Timepidium bromide | Tropicamide | PF-03635659

相关库: Approved Drug Library | Anti-Parkinson's Disease Compound Library | Drug-Fragment Library | CNS-Penetrant Compound Library | NMPA-Approved Drug Library | Orally Active Compound Library | Anti-Alzheimer's Disease Compound Library | NO PAINS Compound Library

酒石酸卡巴拉汀 T1628信息由TargetMol中国为您提供，如您想了解更多关于酒石酸卡巴拉汀 T1628报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途